99 related articles for article (PubMed ID: 24377531)
1. The Kampo medicine Goshajinkigan prevents neuropathy in breast cancer patients treated with docetaxel.
Abe H; Kawai Y; Mori T; Tomida K; Kubota Y; Umeda T; Tani T
Asian Pac J Cancer Prev; 2013; 14(11):6351-6. PubMed ID: 24377531
[TBL] [Abstract][Full Text] [Related]
2. The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen.
Nishioka M; Shimada M; Kurita N; Iwata T; Morimoto S; Yoshikawa K; Higashijima J; Miyatani T; Kono T
Int J Clin Oncol; 2011 Aug; 16(4):322-7. PubMed ID: 21258836
[TBL] [Abstract][Full Text] [Related]
3. Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study.
Oki E; Emi Y; Kojima H; Higashijima J; Kato T; Miyake Y; Kon M; Ogata Y; Takahashi K; Ishida H; Saeki H; Sakaguchi Y; Yamanaka T; Kono T; Tomita N; Baba H; Shirabe K; Kakeji Y; Maehara Y
Int J Clin Oncol; 2015 Aug; 20(4):767-75. PubMed ID: 25627820
[TBL] [Abstract][Full Text] [Related]
4. Potential application of the Kampo medicine goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy.
Cascella M; Muzio MR
J Integr Med; 2017 Mar; 15(2):77-87. PubMed ID: 28285612
[TBL] [Abstract][Full Text] [Related]
5. Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.
Kuriyama A; Endo K
Support Care Cancer; 2018 Apr; 26(4):1051-1059. PubMed ID: 29280005
[TBL] [Abstract][Full Text] [Related]
6. Goshajinkigan reduces oxaliplatin-induced peripheral neuropathy without affecting anti-tumour efficacy in rodents.
Ushio S; Egashira N; Sada H; Kawashiri T; Shirahama M; Masuguchi K; Oishi R
Eur J Cancer; 2012 Jun; 48(9):1407-13. PubMed ID: 21907570
[TBL] [Abstract][Full Text] [Related]
7. Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel.
Pronk LC; Hilkens PH; van den Bent MJ; van Putten WL; Stoter G; Verweij J
Anticancer Drugs; 1998 Oct; 9(9):759-64. PubMed ID: 9840720
[TBL] [Abstract][Full Text] [Related]
8. Goshajinkigan for Low Back Pain: An Observational Study.
Hamaguchi T; Yoshino T; Horiba Y; Watanabe K
J Altern Complement Med; 2017 Mar; 23(3):208-213. PubMed ID: 27991830
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of goshajinkigan for peripheral neurotoxicity of oxaliplatin in patients with advanced or recurrent colorectal cancer.
Kono T; Mamiya N; Chisato N; Ebisawa Y; Yamazaki H; Watari J; Yamamoto Y; Suzuki S; Asama T; Kamiya K
Evid Based Complement Alternat Med; 2011; 2011():418481. PubMed ID: 19952054
[TBL] [Abstract][Full Text] [Related]
10. Goshajinkigan (Chinese herbal medicine niu-che-sen-qi-wan) improves insulin resistance in diabetic rats via the nitric oxide pathway.
Hu X; Sato J; Bajotto G; Khookhor O; Ohsawa I; Oshida Y; Sato Y
Nagoya J Med Sci; 2010 Feb; 72(1-2):35-42. PubMed ID: 20229701
[TBL] [Abstract][Full Text] [Related]
11. Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors.
Eckhoff L; Knoop A; Jensen MB; Ewertz M
Eur J Cancer; 2015 Feb; 51(3):292-300. PubMed ID: 25541155
[TBL] [Abstract][Full Text] [Related]
12. Search of anti-allodynic compounds from Plantaginis Semen, a crude drug ingredient of Kampo formula "Goshajinkigan".
Toume K; Hou Z; Yu H; Kato M; Maesaka M; Bai Y; Hanazawa S; Ge Y; Andoh T; Komatsu K
J Nat Med; 2019 Sep; 73(4):761-768. PubMed ID: 31190267
[TBL] [Abstract][Full Text] [Related]
13. TAXTOX - a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009.
Eckhoff L; Nielsen M; Moeller S; Knoop A
Acta Oncol; 2011 Oct; 50(7):1075-82. PubMed ID: 21824038
[TBL] [Abstract][Full Text] [Related]
14. Goshajinkigan for reducing chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.
Hoshino N; Ganeko R; Hida K; Sakai Y
Int J Clin Oncol; 2018 Jun; 23(3):434-442. PubMed ID: 29270698
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: results of a feasibility study.
Cardoso F; Ferreira Filho AF; Crown J; Dolci S; Paesmans M; Riva A; Di Leo A; Piccart MJ
Anticancer Res; 2001; 21(1B):789-95. PubMed ID: 11299845
[TBL] [Abstract][Full Text] [Related]
16. Effects of Goshajinkigan on insulin resistance in patients with type 2 diabetes.
Uno T; Ohsawa I; Tokudome M; Sato Y
Diabetes Res Clin Pract; 2005 Aug; 69(2):129-35. PubMed ID: 16005362
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer.
Lebowitz PF; Eng-Wong J; Swain SM; Berman A; Merino MJ; Chow CK; Venzon D; Zia F; Danforth D; Liu E; Zujewski J
Clin Cancer Res; 2004 Oct; 10(20):6764-9. PubMed ID: 15501952
[TBL] [Abstract][Full Text] [Related]
18. Drug-interaction between paclitaxel and goshajinkigan extract and its constituents.
Nakayama A; Tsuchiya K; Xu L; Matsumoto T; Makino T
J Nat Med; 2022 Jan; 76(1):59-67. PubMed ID: 34304352
[TBL] [Abstract][Full Text] [Related]
19. Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer.
Eckhoff L; Knoop AS; Jensen MB; Ejlertsen B; Ewertz M
Breast Cancer Res Treat; 2013 Nov; 142(1):109-18. PubMed ID: 24132874
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel-ifosfamide combination in patients with HER2-non-overexpressing advanced breast cancer failing prior anthracyclines.
Kosmas C; Tsavaris N; Malamos N; Tsakonas G; Gassiamis A; Polyzos A; Mylonakis N; Karabelis A
Invest New Drugs; 2007 Oct; 25(5):463-70. PubMed ID: 17370037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
